Blueprint Medicines Corp Stock Alpha and Beta Analysis
| BPMC Stock | USD 89.58 0.26 0.29% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Blueprint Medicines Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Blueprint Medicines over a specified time horizon. Remember, high Blueprint Medicines' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Blueprint Medicines' market risk premium analysis include:
Beta 1.12 | Alpha 0.12 | Risk 3.55 | Sharpe Ratio (0.01) | Expected Return (0.05) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Blueprint |
Blueprint Medicines Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Blueprint Medicines market risk premium is the additional return an investor will receive from holding Blueprint Medicines long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Blueprint Medicines. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Blueprint Medicines' performance over market.| α | 0.12 | β | 1.12 |
Blueprint Medicines expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Blueprint Medicines' Buy-and-hold return. Our buy-and-hold chart shows how Blueprint Medicines performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Blueprint Medicines Market Price Analysis
Market price analysis indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By understating and applying Blueprint Medicines stock market price indicators, traders can identify Blueprint Medicines position entry and exit signals to maximize returns.
Blueprint Medicines Return and Market Media
The median price of Blueprint Medicines for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 94.35 with a coefficient of variation of 9.53. The daily time series for the period is distributed with a sample standard deviation of 9.28, arithmetic mean of 97.39, and mean deviation of 8.0. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Lee Philina of 4331 shares of Blueprint Medicines at 43.15 subject to Rule 16b-3 | 01/10/2025 |
2 | Disposition of 10000 shares by Albers Jeffrey W. of Blueprint Medicines at 36.05 subject to Rule 16b-3 | 01/21/2025 |
3 | Disposition of 816 shares by Christina Rossi of Blueprint Medicines at 110.0 subject to Rule 16b-3 | 01/23/2025 |
4 | Blueprint Medicines Q4 2024 Earnings Preview | 02/12/2025 |
5 | Blueprint Medicines Given Market Outperform Rating at JMP Securities | 02/14/2025 |
6 | Disposition of 2274 shares by Christina Rossi of Blueprint Medicines at 95.14 subject to Rule 16b-3 | 02/20/2025 |
7 | Disposition of 400 shares by Haviland Kate of Blueprint Medicines at 95.4 subject to Rule 16b-3 | 02/21/2025 |
8 | Blueprint Medicines Corporation Among the Oversold Biotech Stocks to Buy Now | 02/24/2025 |
9 | Blueprint Medicines Corp Showcases Promising Data on Mast Cell-Targeted Therapies at ... | 02/28/2025 |
10 | Blueprint Medicines Co. Receives 123.83 Consensus Target Price from Brokerages | 03/03/2025 |
11 | Disposition of 3530 shares by Carter Percy H. of Blueprint Medicines at 88.8 subject to Rule 16b-3 | 03/05/2025 |
12 | Disposition of 2541 shares by Hewes L. Becker of Blueprint Medicines at 87.98 subject to Rule 16b-3 | 03/06/2025 |
13 | Is Blueprint Medicines A Risky Investment | 03/07/2025 |
14 | Blueprint Medicines Co. Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World | 03/10/2025 |
About Blueprint Medicines Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Blueprint or other stocks. Alpha measures the amount that position in Blueprint Medicines Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 4.35 | 12.78 | 3.1 | 1.88 | Revenue Per Share | 3.42 | 4.12 | 8.09 | 8.5 |
Blueprint Medicines Upcoming Company Events
As portrayed in its financial statements, the presentation of Blueprint Medicines' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Blueprint Medicines' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Blueprint Medicines' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Blueprint Medicines. Please utilize our Beneish M Score to check the likelihood of Blueprint Medicines' management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Blueprint Medicines
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Blueprint Medicines Backtesting, Blueprint Medicines Valuation, Blueprint Medicines Correlation, Blueprint Medicines Hype Analysis, Blueprint Medicines Volatility, Blueprint Medicines History and analyze Blueprint Medicines Performance. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.